Stockscreener 앱 받기
9.105
0.65%
-0.115
전일 마감가:
$9.22
열려 있는:
$9.2
하루 거래량:
8,913
Relative Volume:
0.05
시가총액:
$3.21B
수익:
$391.87M
순이익/손실:
$-441.45M
주가수익비율:
-4.9216
EPS:
-1.85
순현금흐름:
$-301.21M
1주 성능:
-9.40%
1개월 성능:
-12.43%
6개월 성능:
-23.48%
1년 성능:
-32.84%
1일 변동 폭
$9.10
$9.20
1주일 범위
$9.12
$10.07
52주 변동 폭
$7.35
$13.79
Alvotech Stock (ALVO) Company Profile
ALVO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
9.105 | 3.21B | 391.87M | -441.45M | -301.21M | -1.85 |
|
RGC
Regencell Bioscience Holdings Ltd
|
63.94 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
154.81 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.46 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.90 | 47.60B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.97 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-14 | 개시 | UBS | Buy |
| 2024-01-29 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-09-21 | 개시 | Barclays | Equal Weight |
| 2022-09-07 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-06 | 다운그레이드 | Citigroup | Buy → Sell |
| 2022-07-26 | 개시 | Citigroup | Buy |
모두보기
Alvotech 주식(ALVO)의 최신 뉴스
Alvotech and Dr. Reddy’s Partner to Develop Biosimilar for Cancer Drug Pembrolizumab - geneonline.com
Short Interest in Alvotech (NASDAQ:ALVO) Grows By 75.2% - MarketBeat
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan - Center for Biosimilars
Alvotech and Dr. Reddy’s Partner to Develop Biosimilar for Keytruda Cancer Drug - geneonline.com
Alvotech, Dr. Reddy’s to co-develop Keytruda biosimilar - Drug Store News
Alvotech (NASDAQ:ALVO) Shares Down 3.3%Here's Why - MarketBeat
Dr. Reddy’s shares rise over 1% on strategic collaboration with Alvotech for Keytruda Biosimilar - MSN
Millennium Management LLC Trims Position in Alvotech (NASDAQ:ALVO) - MarketBeat
Alvotech and Dr. Reddy’s partner to co-develop biosimilar candidate for Merck's Keytruda - MSN
Alvotech and Dr. Reddy’s Partner to Develop Biosimilar of Merck’s Keytruda for Global Cancer Treatment - geneonline.com
Linklaters Advises Syndicate on Alvotech’s SEK 750 Million Private Placement - Global Legal Chronicle
Alvotech Completes Private Placement to Boost Shareholder Base - TipRanks
Alvotech and Dr. Reddy’s Partner to Develop Biosimilar for Pembrolizumab Used in Cancer Treatment - geneonline.com
Alvotech completes private placement with 40 institutional investors By Investing.com - Investing.com Australia
Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors - The Manila Times
Alvotech Completes Successful Private Placement with Global Institutional Investors - Nasdaq
Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors - Yahoo Finance
Alvotech Attracts 40 New Global Investors in Strategic Private Placement, 80% First-Time Buyers - Stock Titan
Alvotech at Goldman Sachs Conference: Strategic Growth in Biosimilars - Investing.com
Alvotech at Goldman Sachs Conference: Strategic Growth in Biosimilars By Investing.com - Investing.com South Africa
Transcript : Alvotech Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 08 - marketscreener.com
Alvotech Partners with Dr. Reddy’s for Keytruda Biosimilar Development - TipRanks
Wall Street Analysts Think Alvotech (ALVO) Could Surge 72.61%: Read This Before Placing a Bet - MSN
Alvotech, Advanz Pharma expand biosimilar deal in Europe - Drug Store News
Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatment - MSN
Dr Reddy’s–Alvotech deal: Why investors are bullish - MSN
Dr Reddys Lab gains on global biosimilar deal with Alvotech - MSN
Alvotech (NASDAQ:ALVO) Stock Price Down 4.8%What's Next? - MarketBeat
Alvotech and Dr. Reddy’s to co-develop biosimilar candidate to Keytruda® (pembrolizumab) - BioSpectrum Asia
Alvotech and Dr. Reddy’s Join Forces to Develop Biosimilar | - Chemical Industry Digest
Alvotech (ALVO) Partners with Dr. Reddy's for Keytruda Biosimila - GuruFocus
Dr Reddy's, Alvotech join hands to co-develop, manufacture & commercialise biosimilar of Merck's blockbuster drug Keytruda - MSN
Alvotech and Dr. Reddy’s partner for Keytruda biosimilar - Pharmaceutical Business review -
Dr Reddy's, Alvotech Partner To Develop Biosimilar For Cancer Treatment - MSN
Alvotech and Dr. Reddy’s to co-develop biosimilar to Keytruda - World Pharmaceutical Frontiers
Dr Reddy’s shares climb over 4% after Keytruda biosimilar deal with Alvotech - MSN
Alvotech to Participate in Goldman Sachs 46th Global Healthcare Conference in Miami - Nasdaq
Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami - Yahoo
Alvotech (ALVO) Trading Down 4.8% on Jun 4 - GuruFocus
Alvotech Completes SEK 750 Million Private Placement to Boost R&D and Market Position - TipRanks
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug - Benzinga
Alvotech (ALVO) Trading Down 4.34% on Jun 5 - GuruFocus
Dr. Reddy’s and Alvotech Collaborate on Keytruda Biosimilar - TipRanks
Dr Reddy’s, Alvotech to co-develop Keytruda biosimilar - The Economic Times
Alvotech (ALVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.84%
0.17%
자본화:
|
볼륨(24시간):